Serina Therapeutics (SER) EBT Margin (2018 - 2025)
Serina Therapeutics (SER) posted EBT Margin of 4581.54% for Q2 2025, down 110.85% sequentially from 42207.14% in Q4 2024, and up 420670.0% YoY from N/an in Q2 2024.
Serina Therapeutics (SER) EBT Margin (2018 - 2025) Analysis & Trends
Serina Therapeutics has reported EBT Margin for 8 years, with the latest figure at 4581.54% in Q2 2025.
- Quarterly EBT Margin rose 420670.0% year-over-year to 4581.54% in Q2 2025, while the trailing twelve-month figure through Dec 2025 was 19263.08% (up 1435121.0% YoY) and the FY2025 annual result came in at 14766.92%, up 524558.0% from the prior year.
- EBT Margin eased to 4581.54% in Q2 2025 per SER's latest filing, from 42207.14% in the prior quarter.
- Over five years, EBT Margin peaked at 42207.14% in Q4 2024 and troughed at 60080.0% in Q1 2024.
- A 5-year average of 14061.12% and a median of 8145.83% in 2021 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2024: EBT Margin jumped 5064667 bps in 2023, then tumbled 5658667 bps in 2024.
- Over 5 years, EBT Margin stood at 1413.75% in 2021, then tumbled by 1476 bps to 22275.0% in 2022, then surged by 100 bps to 14.09% in 2023, then jumped by 299425 bps to 42207.14% in 2024, then plunged by 111 bps to 4581.54% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 4581.54%, 42207.14%, and 38778.57% for Q2 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Serina Therapeutics | 45.80 Mn | 22.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4,581.54% |
| Dec 31, 2024 | 42,207.14% |
| Sep 30, 2024 | -38,778.57% |
| Jun 30, 2024 | -8,788.24% |
| Mar 31, 2024 | -60,080.00% |
| Dec 31, 2023 | 14.09% |
| Sep 30, 2023 | -5,389.66% |
| Jun 30, 2023 | -15,042.86% |
| Mar 31, 2023 | -3,493.33% |
| Dec 31, 2022 | -22,275.00% |
| Sep 30, 2022 | -27,066.67% |
| Jun 30, 2022 | -21,816.67% |
| Mar 31, 2022 | -54,140.00% |
| Dec 31, 2021 | -1,413.75% |
| Sep 30, 2021 | -8,145.83% |
| Jun 30, 2021 | -6,689.19% |
| Mar 31, 2021 | -3,558.93% |
| Dec 31, 2020 | -866.46% |
| Sep 30, 2020 | -3,657.97% |
| Jun 30, 2020 | -5,404.44% |